Duyuru • May 05
UTime Limited has completed a Follow-on Equity Offering in the amount of $1.2 million. UTime Limited has completed a Follow-on Equity Offering in the amount of $1.2 million.
Security Name: Class A Ordinary Shares
Security Type: Common Stock
Price\Range: $1.2
Discount Per Security: $0.072
Security Name: Pre-Funded Warrants
Security Type: Equity Warrant
Price\Range: $0.7
Discount Per Security: $0.042
Transaction Features: Registered Direct Offering Duyuru • May 02
UTime Limited has filed a Follow-on Equity Offering in the amount of $1.2 million. UTime Limited has filed a Follow-on Equity Offering in the amount of $1.2 million.
Security Name: Class A Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,000,000
Price\Range: $1.2
Transaction Features: Registered Direct Offering Reported Earnings • Mar 19
First half 2026 earnings released First half 2026 results: EPS: CN¥113. Revenue: CN¥99.5m (down 28% from 1H 2025). Net income: CN¥9.35m (up CN¥136.7m from 1H 2025). Profit margin: 9.4% (up from net loss in 1H 2025). The move to profitability was driven by lower expenses. New Risk • Feb 27
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (39% average weekly change). Negative equity (-CN¥138m). Earnings have declined by 70% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 233x increase in shares outstanding). Market cap is less than US$10m (US$6.08m market cap). Minor Risk Latest financial reports are more than 6 months old (reported March 2025 fiscal period end). Duyuru • Nov 05
UTime Limited Explores Application of AI Technology in Health Data Analysis UTime Limited outlined its ongoing exploration in the field of health data analysis, particularly the potential application of artificial intelligence (AI) technologies. UTime is developing AI-based algorithm models aimed at performing in-depth analysis of continuous physiological data collected from smart wearable devices such as watches and rings. Current research directions include: building hypertension risk assessment models by integrating multi-parameter data like blood pressure, heart rate, activity and sleep; and conducting trend assessments of users' cardiovascular system health status by analyzing features such as pulse wave morphology. The company explicitly states that all these AI analysis functions are intended to provide users with health trend insights and risk management references and are not substitutes for professional medical diagnosis. Duyuru • Nov 01
UTime Limited Releases Smart Ring, Focusing on Sleep and Continuous Health Monitoring UTime Limited released its smart ring product. Utilizing the advantage of un noticeable wear, the product aims to provide users with nighttime and long-term continuous health data monitoring. This smart ring features a precise and compact design, capable of monitoring multiple physiological parameters including skin temperature, blood oxygen saturation (SpO2), respiratory rate, and heart rate variability (HRV). Its key application scenario is sleep quality assessment, aiming to generate more detailed sleep analysis reports by collecting data unobtrusively during user sleep. Additionally, the product focuses on daily activity tracking and female health cycle management, offering users more comprehensive health insights. Board Change • Oct 31
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Director Minfei Bao is the most experienced director on the board, commencing their role in 2019. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Duyuru • Oct 30
UTime Limited Launches Smartwatch with Integrated Blood Pressure Monitoring UTime Limited announced the launch of a smartwatch with integrated blood pressure monitoring functionality, further expanding its product portfolio in the health technology sector. The product utilizes the Oscillo metric method, a market-validated measurement principle, and integrates a micro air pump and high-precision pressure sensor to provide users with a convenient blood pressure monitoring experience. It has obtained China NMPA Class II Medical Device Registration Certificate (Registration Certificate No.: Guangdong Instrument Note No. 20162070928). In addition to its core blood pressure monitoring feature, the watch also provides multi-dimensional health data references, including heart rate, blood oxygen saturation, sleep analysis, and multiple sports mode tracking. The product design balances wearing comfort with daily practicality and includes interactive features such as voice reminders. Duyuru • Oct 19
UTime Limited has completed a Composite Units Offering in the amount of $25.000003 million. UTime Limited has completed a Composite Units Offering in the amount of $25.000003 million.
Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 22,727,275
Price\Range: $1.1
Discount Per Security: $0.099
Transaction Features: Registered Direct Offering Duyuru • Aug 01
UTime Limited announced delayed 20-F filing On 07/31/2025, UTime Limited announced that they will be unable to file their next 20-F by the deadline required by the SEC. New Risk • Apr 12
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 22% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 41% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 48x increase in shares outstanding). Market cap is less than US$10m (US$4.79m market cap). Duyuru • Mar 27
UTime Announces Reverse Share Split to Regain Compliance with Minimum Bid Price Requirement UTime Limited today announced that it will effect a reverse share split of its outstanding Class A ordinary shares, par value $0.0001 per share (the “Ordinary Shares”), at a ratio of 1-for-10, to be effective on or around the open of trading on March 31, 2025. Our Ordinary Shares will begin trading on a reverse share split-adjusted basis at the opening of The Nasdaq Capital Market (“Nasdaq”) on or around Monday, March 31, 2025. Following the reverse share split, the Ordinary Shares will have a new par value of $0.001 per share and will continue to trade on Nasdaq under the symbol “WTO” with the new CUSIP number, G9411M124. The reverse share split is intended for the Company to regain compliance with the minimum bid price requirement of $1.00 per Ordinary Share for continued listing on Nasdaq. Reported Earnings • Jan 16
First half 2025 earnings released: CN¥192 loss per share (vs CN¥19.15 loss in 1H 2024) First half 2025 results: CN¥192 loss per share (further deteriorated from CN¥19.15 loss in 1H 2024). Revenue: CN¥138.4m (up 65% from 1H 2024). Net loss: CN¥127.3m (loss widened CN¥116.9m from 1H 2024). New Risk • Sep 16
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (37% average weekly change). Shareholders have been substantially diluted in the past year (over 32x increase in shares outstanding). Minor Risk Market cap is less than US$100m (US$11.9m market cap). Duyuru • Sep 10
UTime Announces 1-for-25 Reverse Share Split Intended to Regain Compliance with the Minimum Bid Price Requirement UTime Limited announced that it will effect a reverse share split of its outstanding ordinary shares, par value $0.0001 per share (the “Ordinary Shares”), at a ratio of 1-for-25, to be effective on or around the open of trading on September 11, 2024. Our Ordinary Shares will begin trading on a reverse share split-adjusted basis at the opening of The Nasdaq Capital Market (“Nasdaq”) on or around September 11, 2024. Following the reverse share split, the Ordinary Shares will have a par value of $0.0001 per share and will continue to trade on Nasdaq under the symbol “WTO” with the new CUSIP number, G9411M116. The reverse share split is intended for the Company to regain compliance with the minimum bid price requirement of $1.00 per ordinary share for continued listing on Nasdaq. Duyuru • Aug 26
UTime Limited Develops Core Continuous Blood Pressure Measurement Technology System UTime Limited announced its collaboration on Circul VS, a core continuous blood pressure measurement technology system developed in partnership with strategic partner, Dr. Ehud Baron. Designed to offer patients an accurate and user-friendly continuous blood pressure monitoring solution, Circul VS facilitates early detection and long-term management, helping to reduce the risks associated with cardiovascular and cerebrovascular conditions. Circul VS features the BPwatch, Ring, and Smart Cradle, integrated into a sophisticated cloud-based network and service system. Unlike other systems on the market, Circul VS focuses on capturing rapid blood pressure fluctuations caused by changes in endothelial function and vascular tone—critical factors often neglected by competitors. Utilizing ultrasound sensing technology and intelligent algorithms, Circul VS provides continuous, real-time blood pressure waveform data with exceptional accuracy. This innovative technology is the result of comprehensive market research and extensive clinical studies. As part of this strategic collaboration, UTime has harnessed expertise in biomedical engineering and electronic technology to ensure the Circul VS system is not only precise but also stable and reliable in diverse clinical settings. Having undergone clinical trials in multiple partner hospitals, Circul VS has garnered positive feedback for its outstanding performance in the non-invasive monitoring space, offering systolic and diastolic pressure readings with accuracy approaching that of invasive techniques. During its development, Circul VS was tailored to meet the needs of different application scenarios—including hypertension screening for healthy individuals, long-term management for diagnosed hypertension patients, and acute monitoring for hospitalized patients. This adaptability ensures it meets the specific demands of various clinical environments. The launch of Circul VS marks a pivotal advancement in blood pressure monitoring technology. Together with Dr. Ehud Baron, UTime plans to continue refining this technology, aiming to enhance its intelligence and accuracy for widespread use in ICUs and other medical settings, ultimately improving patient care and quality of life. Duyuru • Aug 15
UTime Regains Compliance with Nasdaq Minimum ClosingBid Price Rule UTime Limited announced that it received a formal notification from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires the Company’s ordinary shares to maintain a minimum bid price of $1.00 per share. The Nasdaq staff made this determination of compliance after the closing bid price of the Company’s common stock has been at $1.00 per share or greater for the last 11 consecutive business days from July 26, 2024 to August 9, 2024. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and this bid price deficiency matter is now closed. Reported Earnings • Aug 01
Full year 2024 earnings released: CN¥1.95 loss per share (vs CN¥7.80 loss in FY 2023) Full year 2024 results: CN¥1.95 loss per share (improved from CN¥7.80 loss in FY 2023). Revenue: CN¥172.2m (down 14% from FY 2023). Net loss: CN¥32.3m (loss narrowed 63% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 44% per year, which means it is performing significantly worse than earnings. New Risk • Apr 09
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 22% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 48% per year over the past 5 years. Shareholders have been substantially diluted in the past year (121% increase in shares outstanding). Market cap is less than US$10m (US$3.38m market cap). New Risk • Feb 24
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 41% per year over the past 5 years. Shareholders have been substantially diluted in the past year (64% increase in shares outstanding). Market cap is less than US$10m (US$3.79m market cap). Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Share price has been volatile over the past 3 months (14% average weekly change). Board Change • Nov 01
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Director Minfei Bao is the most experienced director on the board, commencing their role in 2019. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Duyuru • Aug 03
UTime Limited announced delayed 20-F filing On 08/01/2023, UTime Limited announced that they will be unable to file their next 20-F by the deadline required by the SEC. Board Change • Jul 23
Less than half of directors are independent There are 4 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Xiaoqian Jia is the most experienced director on the board, commencing their role in 2023. They were also the last independent director to join the board. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. Duyuru • Jul 21
UTime Limited Announces Directorate Changes UTime Limited announced on July 11, 2023, Mr. David Bolocan notified the Company of his resignation as a director of the Company, effective July 11, 2023. On July 11, 2023, Mr. Mo Zou notified the Company of his resignation as a director of the Company, effective July 11, 2023. on July 11, 2023, the board of directors of the Company appointed Ms. Na Cai to serve as a director and the Chairwoman of the Audit Committee of the Company, effective July 11, 2023. Ms. Cai, age 37, has over 10 years of financial and managerial experience in the technology and financial service industry. Since 2015, Ms. Cai has served as a director of Bluestone Securities (HK) Co., Limited and the Chief Financial Officer of Bluestone International Holdings (HK) Co. Ltd. She was the Finance Manager at Shenzhen Qianhai Sanchuan Asset Management Co. Ltd. between 2013 and 2015. From 2011 to 2013, Ms. Cai served as the Finance Controller of Shenzhen Qingfengyuan Environmental Protection Technology Co. Ltd. During her tenure, Ms. Cai demonstrated leadership and experience in financial management, strategy development, and operations. Ms. Cai received her bachelor’s degree from Taishan Medical College, now known as Shandong First Medical University. To fill in the vacancy created by the resignation of Mr. Zou, To fill in the vacancy created by the resignation of Mr. Bolocan, on July 11, 2023, the Board appointed Mr. Hailin Xie to serve as a director and the Chairman of Compensation Committee of the Company, effective July 11, 2023. Mr. Xie, age 43, has over 20 years of business development and managerial experience in the healthcare industry. Since 2000, Mr. Xie has established several businesses in the healthcare industry that research, develop, and manufacture health supplements in China. Mr. Xie is the Chairman of Guangxi Fuxingyi Investment Group and the President of Guangxi God Fly Investment Group. Mr. Xie attended Guangxi University, where he majored in marketing. New Risk • Jul 19
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$4.77m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (71% average weekly change). Earnings have declined by 31% per year over the past 5 years. Market cap is less than US$10m (US$4.77m market cap). Reported Earnings • Mar 27
First half 2023 earnings released: CN¥1.75 loss per share (vs CN¥1.14 loss in 1H 2022) First half 2023 results: CN¥1.75 loss per share (further deteriorated from CN¥1.14 loss in 1H 2022). Revenue: CN¥127.8m (up 27% from 1H 2022). Net loss: CN¥14.3m (loss widened 53% from 1H 2022). Board Change • Nov 16
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. CEO & Chairman of the Board Minfei Bao is the most experienced director on the board, commencing their role in 2018. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 31
Full year 2022 earnings released: CN¥4.76 loss per share (vs CN¥3.68 loss in FY 2021) Full year 2022 results: CN¥4.76 loss per share (further deteriorated from CN¥3.68 loss in FY 2021). Revenue: CN¥275.5m (up 12% from FY 2021). Net loss: CN¥38.8m (loss widened 134% from FY 2021). Board Change • Oct 29
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. CEO & Chairman of the Board Minfei Bao is the most experienced director on the board, commencing their role in 2018. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Duyuru • Aug 25
UTime Limited Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 20-F United Time Technology Co., Ltd. (UTime Limited) announced that it has received a notice (“Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) as a result of its failure to file its Annual Report on Form 20-F for the fiscal year ended March 31, 2022 (the “Form 20-F”) in a timely fashion. The Notice advised the Company that it was not in compliance with Nasdaq’s continued listing requirements under the timely filing criteria established in Nasdaq Listing Rule 5250(c)(1) (the “Rule”). As reported by the Company in its Form 12b-25 filed with the Securities and Exchange Commission (the “SEC”) on July 29, 2022, the Company was unable to file its Form 20-F within the prescribed time period without unreasonable effort or expense. The extension period provided under Rule 12b-25 expired on August 16, 2022. Nasdaq has informed the Company that, under Nasdaq rules, the Company will be required to submit a plan to regain compliance with Rule 5250(c)(1) for the Staff’s consideration by no later than October 17, 2022, which is 60 calendar days from receipt of the Notice. If the Staff accepts the plan, the Staff may grant the Company an extension of up to 180 calendar days from the Form 20-F’s due date, or until February 13, 2023 to regain compliance. However, there can be no assurance that Nasdaq will accept the Company’s plan to regain compliance or that the Company will be able to regain compliance within any extension period granted by Nasdaq. If the Staff does not accept the Company’s plan, then the Company will have the opportunity to appeal that decision to a Nasdaq Hearings Panel. The Notice has no immediate effect on the listing or trading of the Company’s securities. However, if the Company fails to timely regain compliance with the Rule, the Company’s securities will be subject to delisting from Nasdaq. The Company is working diligently to complete its Form 20-F and intends to file the Form 20-F as soon as practicable to regain compliance with the Rules. Duyuru • Jul 30
United Time Technology Co., Ltd. announced delayed 20-F filing On 07/29/2022, United Time Technology Co., Ltd. announced that they will be unable to file their next 20-F by the deadline required by the SEC. Duyuru • May 29
UTime Limited Announces Board Changes UTime Limited announced that the company’s Board of Directors has appointed Weiyuan Wang to the Board. Mr. Wang will serve as an independent Board member and will also serve as the Chairman of the Nominating and Corporate Governance Committee and the member of the Audit Committee and the Compensation Committee of the Board of Directors. Mr. Wang joins the UTime Board of Directors following the voluntary resignation of Lawrence Eckles from the Board of Directors for personal reasons. Board Change • Apr 27
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. CEO & Chairman of the Board Minfei Bao is the most experienced director on the board, commencing their role in 2018. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Apr 01
First half 2022 earnings released First half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (down CN¥6.96m from profit in 1H 2021). Profit margin: (down from 3.9% in 1H 2021). The decrease in margin was driven by lower expenses. Reported Earnings • Jul 25
Full year 2021 earnings released: CN¥3.68 loss per share (vs CN¥4.82 loss in FY 2020) The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: CN¥246.9m (up 28% from FY 2020). Net loss: CN¥16.6m (loss narrowed 23% from FY 2020).